Glaxo Wellcome Inc.

Smithkline Beecham Corporation

Burroughs Wellcome Co.

Medical University of South Carolina

Glaxosmithkline LLC

University College Cardiff Consultants Limited

The Wellcome Foundation Limited

Glaxo Wellsome Inc.

Karl Witold Franzmann

Harold Francis Hodson

David Alan Sawyer

Richard Graham Knowles

Martin James Drysdale

Barry George Shearer

Simon T Hodgson

Peter John Wates

John Gordon Dann

Richard James Arrowsmith

Richard Mansfield Beams

Anthony Joseph Frend

Daryl David Rees

Patricia Ifeyinwa Davies

George Stuart Cockerill

Alan T Hudson

Stephen Barry Guntrip

Kathryn Jane Smith

Richard Michael John Palmer

Paul Barraclough

James M Chapman, Jr

Patrick Vivian Shannon

Laddawan Chunchatprasert

Sadie Vile

Richard Michael Palmer

Martin John Page

Stephen Carl McKeown

Steven Smith

Helen Alice Rebecca Clark

Jeremy Nigel Stables

Nagaraja Kodanda Rao

Kevin Julian O'Connor

Roy Lee Hawke

Helen Alice Clark

Enzyme inhibitors

Nitric oxide synthase inhibitors

Substituted heteroaromatic compounds of formula (A) wherein X is N or CH; in which (a) represents a fused 5, 6 or 7-membered heterocyclic ring and R,is a group ZR,wherein Z is joined to R,through a (CH,)p group in which p is 0, 1, or 2 and Z represents a group V(CH,), V(CF,), (CH,)V, (CF,)V, V(CRR&prime;), V(CHR) or V where R and R&prime; are each C,alkyl and in which V is a hydrocarbyl group containing 0, 1 or 2 carbon atoms, carbonyl, dicarbonyl, CH(OH), CH(CN), sulphonamide, amide, O, S(O),or NR,where R,is hydrogen or R,is C,alkyl; and R,is an optionally substituted C,cycloalkyl or an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety; or R,is a group ZR,in which Z is NR,, and NR,and R,together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety, are protein tyrosine kinase inhibitors. The compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of psoriasis, fibrosis, atherosclerosis, restenosis, auto-immune disease, allergy, asthma, transplantation rejection, inflammation, thrombosis, nervous system diseases, and cancer.

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

The present invention is concerned with diaryl compounds of formula (I) and their use in medical therapy, particularly in the prophylaxis or treatment of a clinical condition for which an ACAT inhibitor is indicated, such as hyperlipidaema or atherosclerosis. The invention also relates to pharmaceutical compositions and processes for the preparation of compounds according to the invention. ##STR1##

Anti-atherosclerotic diaryl compounds

Aminoacid derivatives as no synthase inhibitors

The invention relates to compounds of formula (I) which have been found to possess anti-tumor activity. Pharmaceutical compositions and methods of treating tumors are also disclosed. ##STR1##

Tetracyclic compounds, intermediates for their preparation and their use

The present invention is concerned with compounds of formula (I) ##STR1## wherein Ar is a mono- or bicyclic aromatic group optionally containing one or two heteroatoms independently selected from nitrogen, oxygen and sulphur, said group being optionally substituted by one or more atoms or groups independently selected from halogen, nitro, amino, --NRR.sup.1 where R and R.sup.1 are independently selected from hydrogen, C.sub.1-8 alkyl and C.sub.1-8 alkanoyl, cyano, carboxyalkoxy, alkoxycarbonylalkoxy, C.sub.1-8 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.1-8 alkoxy (including cycloalkoxy and cycloalkylalkoxy), C.sub.1-8 thioalkyl, said alkyl, alkoxy and/or thioalkyl group(s) being optionally substituted by one or more halogen atoms, aryl, aryloxy, aralkyl and aralkyloxy, said aryl, aryloxy, aralkyl and/or aralkyloxy group(s) being optionally substituted by one or more atoms or groups independently selected from halogen, alkyl, alkoxy, alkanoyl, hydroxyalkyl, perfluoroalkyl, perfluoroalkoxy, carboxyalkoxy, alkoxycarbonylalkoxy, and C.sub.3-8 polyether groups containing from one to three oxygen atoms;

Anti-atherosclerotic aryl compounds

Compounds of the formula (III): ##STR1## or salts or acyl derivatives thereof, for use as antifungal and antiprotozoal agents are disclosed. Compositions containing the compounds are also disclosed as are method for the preparation of the compounds and intermediates in their preparation.

Nitrogen containing heterocyclic compounds

Growing community of inventors

Beckenham, United Kingdom

Karl Witold Franzmann